Expect Trikafta to Be a Game Changer for Cystic Fibrosis
Trikafta (try-KAF-tuh, elexacaftor/tezacaftor/ivacaftor) will be a game changer for treating cystic fibrosis (CF).
It targets a gene mutation found in nearly 90% of CF patients.
CF transmembrane conductance regulator (CFTR) modulators already on the market...Kalydeco, Orkambi, and Symdeko...target genetic mutations found in fewer than 50% of patients.
Get unlimited access through an Enterprise license
Hospital Pharmacist's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 300+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Not sold to individuals